China Health Group Inc. (“China Health Group”; stock code: 08225) has announced plans to seek shareholder approval for a new 10-year share option scheme (“New Scheme”) at its annual general meeting (AGM) scheduled for 17 July 2026. The move follows the expiry of the company’s pre-IPO and post-IPO option plans, under which all outstanding options have either been exercised or lapsed.

Key features of the proposed New Scheme are as follows:

• Scheme size and limits: – Overall cap: Shares issuable under all outstanding options may not exceed 30% of China Health Group’s issued share capital at any time. – Scheme mandate: New grants under all share schemes are limited to 10% of issued share capital on the approval date; exercised or lapsed options will not be counted. – Individual cap: Any single participant may not receive options representing more than 1% of issued share capital within a 12-month period without separate shareholder approval.

• Eligibility: Directors, full-time or part-time employees, consultants, contractors, related discretionary trusts and beneficially-owned companies of the Group.

• Pricing and vesting: – Exercise price will be the highest of (i) the closing price on the grant date, (ii) the average closing price over the five preceding business days, and (iii) the nominal share value of HK$0.10. – A minimum vesting period of 12 months applies, except in limited circumstances such as death, takeover, or winding-up.

• Tenor and exercise window: Options are exercisable for up to 10 years from the grant date; unexercised options lapse thereafter.

• Connected persons: Grants exceeding 0.1% of issued capital or HK$5.00 million in value to substantial shareholders, independent non-executive directors or their associates within any 12-month period will require separate shareholder approval, with connected persons abstaining from voting.

Implementation of the New Scheme is contingent on (1) shareholder approval at the 17 July 2026 AGM and (2) the Stock Exchange’s grant of listing and dealing permission for the underlying shares.

The Board, including all independent non-executive directors, regards the New Scheme as an effective instrument to align employee interests with long-term corporate performance and recommends shareholders vote in favour of its adoption.

The full scheme document will be available for inspection at the company’s Hong Kong office up to and including the AGM date, and a detailed circular will be dispatched to shareholders and uploaded to the HKEXnews website.